{
  "source_file": "cdiscpilot01.pdf",
  "source_pages": 492,
  "extraction_date": "2026-02-27T15:05:21Z",
  "narrative": {
    "file": "pdf/narrative_body.pdf",
    "pages_in_source": [
      1,
      42
    ],
    "page_count": 42
  },
  "tlfs": [
    {
      "id": "Table 14-1.01",
      "type": "table",
      "title": "Summary of Populations",
      "file": "pdf/Table_14-1.01.pdf",
      "pages_in_source": [
        43,
        43
      ],
      "page_count": 1,
      "population": "All Subjects"
    },
    {
      "id": "Table 14-1.02",
      "type": "table",
      "title": "Summary of End of Study Data",
      "file": "pdf/Table_14-1.02.pdf",
      "pages_in_source": [
        44,
        44
      ],
      "page_count": 1,
      "population": "Intent-to-Treat"
    },
    {
      "id": "Table 14-1.03",
      "type": "table",
      "title": "Summary of Number of Subjects By Site",
      "file": "pdf/Table_14-1.03.pdf",
      "pages_in_source": [
        45,
        45
      ],
      "page_count": 1,
      "population": "All Subjects"
    },
    {
      "id": "Table 14-2.01",
      "type": "table",
      "title": "Summary of Demographic and Baseline Characteristics",
      "file": "pdf/Table_14-2.01.pdf",
      "pages_in_source": [
        46,
        48
      ],
      "page_count": 3,
      "population": "Intent-to-Treat"
    },
    {
      "id": "Table 14-3.01",
      "type": "table",
      "title": "Primary Endpoint Analysis: ADAS Cog (11) - Change from Baseline to Week 24 - LOCF",
      "file": "pdf/Table_14-3.01.pdf",
      "pages_in_source": [
        49,
        49
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.02",
      "type": "table",
      "title": "Primary Endpoint Analysis: CIBIC+ - Summary at Week 24 - LOCF",
      "file": "pdf/Table_14-3.02.pdf",
      "pages_in_source": [
        50,
        50
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.03",
      "type": "table",
      "title": "ADAS Cog (11) - Change from Baseline to Week 8 - LOCF",
      "file": "pdf/Table_14-3.03.pdf",
      "pages_in_source": [
        51,
        51
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.04",
      "type": "table",
      "title": "CIBIC+ - Summary at Week 8 - LOCF",
      "file": "pdf/Table_14-3.04.pdf",
      "pages_in_source": [
        52,
        52
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.05",
      "type": "table",
      "title": "ADAS Cog (11) - Change from Baseline to Week 16 - LOCF",
      "file": "pdf/Table_14-3.05.pdf",
      "pages_in_source": [
        53,
        53
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.06",
      "type": "table",
      "title": "CIBIC+ - Summary at Week 16 - LOCF",
      "file": "pdf/Table_14-3.06.pdf",
      "pages_in_source": [
        54,
        54
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.07",
      "type": "table",
      "title": "ADAS Cog (11) - Change from Baseline to Week 24 - Completers at Wk 24-Observed Cases-Windowed",
      "file": "pdf/Table_14-3.07.pdf",
      "pages_in_source": [
        55,
        55
      ],
      "page_count": 1,
      "population": "Completers"
    },
    {
      "id": "Table 14-3.08",
      "type": "table",
      "title": "ADAS Cog (11) - Change from Baseline to Week 24 in Male Subjects - LOCF",
      "file": "pdf/Table_14-3.08.pdf",
      "pages_in_source": [
        56,
        56
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.09",
      "type": "table",
      "title": "ADAS Cog (11) - Change from Baseline to Week 24 in Female Subjects - LOCF",
      "file": "pdf/Table_14-3.09.pdf",
      "pages_in_source": [
        57,
        57
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.10",
      "type": "table",
      "title": "ADAS Cog (11) - Mean and Mean Change from Baseline over Time",
      "file": "pdf/Table_14-3.10.pdf",
      "pages_in_source": [
        58,
        58
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.11",
      "type": "table",
      "title": "ADAS Cog (11) - Repeated Measures Analysis of Change from Baseline to Week 24",
      "file": "pdf/Table_14-3.11.pdf",
      "pages_in_source": [
        59,
        59
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.12",
      "type": "table",
      "title": "Mean NPI-X Total Score from Week 4 through Week 24 - Windowed",
      "file": "pdf/Table_14-3.12.pdf",
      "pages_in_source": [
        60,
        60
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-3.13",
      "type": "table",
      "title": "CIBIC+ - Categorical Analysis - LOCF",
      "file": "pdf/Table_14-3.13.pdf",
      "pages_in_source": [
        61,
        61
      ],
      "page_count": 1,
      "population": "Efficacy"
    },
    {
      "id": "Table 14-4.01",
      "type": "table",
      "title": "Summary of Planned Exposure to Study Drug, as of End of Study",
      "file": "pdf/Table_14-4.01.pdf",
      "pages_in_source": [
        62,
        62
      ],
      "page_count": 1,
      "population": "Safety"
    },
    {
      "id": "Table 14-5.01",
      "type": "table",
      "title": "Incidence of Treatment Emergent Adverse Events by Treatment Group",
      "file": "pdf/Table_14-5.01.pdf",
      "pages_in_source": [
        63,
        78
      ],
      "page_count": 16,
      "population": "Safety"
    },
    {
      "id": "Table 14-5.02",
      "type": "table",
      "title": "Incidence of Treatment Emergent Serious Adverse Events by Treatment Group",
      "file": "pdf/Table_14-5.02.pdf",
      "pages_in_source": [
        79,
        79
      ],
      "page_count": 1,
      "population": "Safety"
    },
    {
      "id": "Table 14-6.01",
      "type": "table",
      "title": "Summary Statistics for Continuous Laboratory Values",
      "file": "pdf/Table_14-6.01.pdf",
      "pages_in_source": [
        80,
        94
      ],
      "page_count": 15,
      "population": "Safety"
    },
    {
      "id": "Table 14-6.02",
      "type": "table",
      "title": "Frequency of Normal and Abnormal (Beyond Normal Range) Laboratory Values During Treatment",
      "file": "pdf/Table_14-6.02.pdf",
      "pages_in_source": [
        95,
        96
      ],
      "page_count": 2,
      "population": "Safety"
    },
    {
      "id": "Table 14-6.03",
      "type": "table",
      "title": "Frequency of Normal and Abnormal (Clinically Significant Change from Previous Visit) Laboratory Values",
      "file": "pdf/Table_14-6.03.pdf",
      "pages_in_source": [
        97,
        98
      ],
      "page_count": 2,
      "population": "Safety"
    },
    {
      "id": "Table 14-6.04",
      "type": "table",
      "title": "Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit",
      "file": "pdf/Table_14-6.04.pdf",
      "pages_in_source": [
        99,
        131
      ],
      "page_count": 33,
      "population": "Safety"
    },
    {
      "id": "Table 14-6.05",
      "type": "table",
      "title": "Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges",
      "file": "pdf/Table_14-6.05.pdf",
      "pages_in_source": [
        132,
        137
      ],
      "page_count": 6,
      "population": "Safety"
    },
    {
      "id": "Table 14-6.06",
      "type": "table",
      "title": "Shifts of Hy's Law Values During Treatment",
      "file": "pdf/Table_14-6.06.pdf",
      "pages_in_source": [
        138,
        138
      ],
      "page_count": 1,
      "population": "Safety"
    },
    {
      "id": "Table 14-7.01",
      "type": "table",
      "title": "Summary of Vital Signs at Baseline and End of Treatment",
      "file": "pdf/Table_14-7.01.pdf",
      "pages_in_source": [
        139,
        143
      ],
      "page_count": 5,
      "population": "Safety"
    },
    {
      "id": "Table 14-7.02",
      "type": "table",
      "title": "Summary of Vital Signs Change from Baseline at End of Treatment",
      "file": "pdf/Table_14-7.02.pdf",
      "pages_in_source": [
        144,
        147
      ],
      "page_count": 4,
      "population": "Safety"
    },
    {
      "id": "Table 14-7.03",
      "type": "table",
      "title": "Summary of Weight Change from Baseline at End of Treatment",
      "file": "pdf/Table_14-7.03.pdf",
      "pages_in_source": [
        148,
        148
      ],
      "page_count": 1,
      "population": "Safety"
    },
    {
      "id": "Table 14-7.04",
      "type": "table",
      "title": "Summary of Concomitant Medications (Number of Subjects)",
      "file": "pdf/Table_14-7.04.pdf",
      "pages_in_source": [
        149,
        150
      ],
      "page_count": 2,
      "population": "Safety"
    },
    {
      "id": "Figure 14-1",
      "type": "figure",
      "title": "Time to Dermatologic Event by Treatment Group",
      "file": "pdf/Figure_14-1.pdf",
      "pages_in_source": [
        151,
        151
      ],
      "page_count": 1,
      "population": "Safety",
      "source_program": "C:\\cdisc_pilot\\PROGRAMS\\DRAFT\\TFLs\\kmfigure.sas"
    }
  ]
}